Lenalidomide in lymphomas and chronic lymphocytic leukemia

Bibliography

• Vallet S, Palumbo A, Raje N, Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008;49:1238-45
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Li H, Gardner ER, Figg WD. Thalidomide analogues as anticancer drugs. Recent Patents Anticancer Discov 2007;2:167-74
   PubMed Web of Science ®Google Scholar
• Paravar T, Lee DJ. Thalidomide: mechanisms of action. Int Rev Immunol 2008;27:111-35
   PubMed Web of Science ®Google Scholar
• Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther 2012;136:56-68
   PubMed Web of Science ®Google Scholar
• Verhelle D, Corral LG, Wong K, Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007;67:746-64
   PubMed Web of Science ®Google Scholar
• Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid ® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-59
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Ma W, Wang ZQ, Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 2011;286:11009-20
   PubMed Web of Science ®Google Scholar
• Kim Y, Alpmann P, Blaum-Feder S, Increased in vivo efficacy of lenalidomide by addition of piroctone olamine. In vivo 2011;25:99-103
   PubMed Web of Science ®Google Scholar
• Schmidt M, Kim Y, Gast SM, Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid. In Vivo 2011;25:325-33
   PubMed Web of Science ®Google Scholar
• Lu L, Payvandi F, Wu L, The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc Res 2009;77:78-86
   PubMed Web of Science ®Google Scholar
• Wu L, Adams M, Carter T, Lenalidomide enhances natural killer cells and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650-7
   PubMed Web of Science ®Google Scholar
• McDaniel JM, Pinilla-Ibarz J, Epling-Burnette PK. Molecular action of lenalidomide in lymphocytes and hematologic malignancies. Adv Hematol 2012;2012:513702
   PubMedGoogle Scholar
• Lopez-Girona A, Mendy D, Ito T, Cerblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 2012;26:2445
   Web of Science ®Google Scholar
• Yang Y, Shaffer AL III, Emre NC, Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012;21(6):723-37
   PubMed Web of Science ®Google Scholar
• Liu Q, Farley KL, Johnson KA, Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma. Ther Drug Monit 2008;30:620-7
   PubMed Web of Science ®Google Scholar
• Chen N, Lau H, Kong L, Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. Clin Pharmacol 2007;47:1466-75
   Google Scholar
• Blansfield JA, Caragacianu D, Alexander HR III, Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008;14:270-80
   PubMed Web of Science ®Google Scholar
• Cosenza M, Civallero M, Grisendi G, Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Ann Hematol 2012;91:1613-22
   PubMed Web of Science ®Google Scholar
• Moutouh-de Parseval LA, Verhelle D, Glezer E, Pomalidomide and lenalidomide regulate eryhtropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest 2008;118:248-58
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide. Blood 2012;120:1412-21
   PubMed Web of Science ®Google Scholar
• Sher T, Miller KC, Lawrence D, Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-6
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Porter CW. Immunomodulating drugs for chronic lymphocytic leukemia. Lancet Oncol 2006;7:480-8
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Takeshita K, Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 2005;106:3348-52
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Musial L, Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006;24:5343-9
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, Lee BN, Schlette EJ, Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008;111:5291-7
   PubMed Web of Science ®Google Scholar
• Andritsos LA, Johnson AJ, Lozanski G, Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:2519-25
   PubMed Web of Science ®Google Scholar
• Moutouh-de-Parseval LA, Weiss L, DeLap RJ, Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia. J Clin Oncol 2007;25:5047
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Whitworth A, Bangia N, Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol 2008;26:4851-2
   PubMed Web of Science ®Google Scholar
• Aue G, Njuguna N, Tian X, Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia. Haematologica 2009;94:1266-73
   PubMed Web of Science ®Google Scholar
• Lapalombella R, Yu B, Triantafillou G, Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 2008;112:5180-9
   PubMed Web of Science ®Google Scholar
• Srinivasan S, Schiffer CA. Concurrent B-cell chronic lymphocytic leukemia and multiple myeloma treated successfully with lenalidomide. Leuk Res 2009;33:561-4
   PubMed Web of Science ®Google Scholar
• Makower D, Venkatraj U, Dutcher JP, Wiernik PH. Occurrence of myeloma in a chronic lymphocytic leukemia patient after response to differentiation therapy with interleukin-4. Leuk Lymphoma 1996;23:617-19
   PubMed Web of Science ®Google Scholar
• Gentile M, Recchia AG, Vigna E, Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2011;20:273-86
   PubMed Web of Science ®Google Scholar
• Boll B, Borchmann P, Topp MS, Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010;148:480-2
   PubMed Web of Science ®Google Scholar
• Boll B, Fuchs M, Reiners KS, Lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2010;116:abstract 2828
   Google Scholar
• Corazzeli G, De Filippi R, Capobianco G, Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. Am J Hematol 2010;85:87-90
   PubMed Web of Science ®Google Scholar
• Mandac I, Kolonic SO. Lenalidomide induced good clinical response in a patient with multiple relapsed and refractory Hodgkin's lymphoma. J Hematol Oncol 2010;3:20
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Taylor D, Wang L, Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2008;112:abstract 3052
   Google Scholar
• Currin ES, Gopal AK. Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation. Korean J Hematol 2012;47:8-16
   PubMedGoogle Scholar
• Rothe A, Sasse S, Goergen H, Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. Blood 2012;120:1470-2
   PubMed Web of Science ®Google Scholar
• Tempescul A, Ianotto JC, Evillard JR, ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation. Ann Hematol 2011;90:971-3
   PubMed Web of Science ®Google Scholar
• Tempescul A, Ianotto JC, Guillerm G, Berthou C. ESAP-lenalidomide- a highly active regimen in refractory or relapsed Hodgkin's lymphoma. Blood 2009;114:abstract 4797
   Google Scholar
• Determann O, Hoster E, Ott G, Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL network and the German low grade lymphoma study group. Blood 2008;111:2385-7
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185-97
   PubMed Web of Science ®Google Scholar
• Kluin-Nelemans HC, Hoster E, Hermine O, Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367:520-31
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Hoster E, Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German low grade lymphoma study group (GLSG). J Clin Oncol 2005;23:1984-92
   PubMed Web of Science ®Google Scholar
• Herrmann A, Hoster E, Zwingers T, Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-18
   PubMed Web of Science ®Google Scholar
• Kahl BS, Longo WL, Eickhoff JC, Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006;17:1418-23
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G, Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study group indolent lymphomas, Germany). Blood 2009;114:abstract 405
   Web of Science ®Google Scholar
• Hitz F, Martinelli G, Zucca E, A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. Hematol Oncol 2009;27:154-9
   PubMed Web of Science ®Google Scholar
• Jurczak W, Giza AB, Skotnicki A, Use of radioimmunotherapy for consolidation for chemosensitive mantle cell lymphoma (MCL): summary of international radioimmunotherapy registry data [abstract]. J Clin Oncol 2010;28:e18519
   Web of Science ®Google Scholar
• Hess G, Herbrecht R, Romaguera J, Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009;27:3822-9
   PubMed Web of Science ®Google Scholar
• Spurgeon SE, Pindyck T, Okada C, Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2011;52:1488-94
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson JL, Jung S, A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB50501): results of a planned interim analysis. J Clin Oncol 2010;28(15s):abstract 8106
   Google Scholar
• Advani RH, Buggy JJ, Sharman JP, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol 2013;31:88-94
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952-7
   PubMed Web of Science ®Google Scholar
• Habermann TM, Lossos IS, Justice G, Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-9
   PubMed Web of Science ®Google Scholar
• Reeder CB, Witzig TE, Zinzani JM, Efficay and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003). J Clin Oncol 2009;27(15s):abstract 8569
   Google Scholar
• Eve HE, Carey S, Richardson SJ, Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159:154-63
   PubMed Web of Science ®Google Scholar
• Tempescul A, Ianotto JC, Morel F, Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol 2009;88:921-2
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, An international phase II trial of single-agent lenalidomide for relapsed and refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011;22:1622-7
   PubMed Web of Science ®Google Scholar
• Gunnellin M, Falchi L. Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non-Hodgkin's lymphomas. Adv Hematol 2012;2012:523842
   PubMedGoogle Scholar
• Qian Z, Zhang L, Cai Z, Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 2011;35:380-6
   PubMed Web of Science ®Google Scholar
• Zaja F, De Luca S, Vitolo U, Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012;97:416-22
   PubMed Web of Science ®Google Scholar
• Zhang L, Qian Z, Cai Z, Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84:553-9
   PubMed Web of Science ®Google Scholar
• Wang M, Fayad L, Wagner-Bartak N, Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1-2 clinical trial. Lancet Oncol 2012;13:716-23
   PubMed Web of Science ®Google Scholar
• Eve HE, Rule SA. Lenalidomide-induced tumour flare reaction in mantle cell lymphoma. Br J Haematol 2010;151:410-12
   PubMed Web of Science ®Google Scholar
• Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011;117:26-38
   PubMed Web of Science ®Google Scholar
• Dawar R, Hernandez-Illizaliturri F. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL). Best Pract Res Clin Haematol 2012;25:185-90
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Reale MA, Bauer F. Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide. Leuk Res 2010;34:e178-80
   PubMed Web of Science ®Google Scholar
• Ramsay AG, Clear AJ, Kelly G, Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009;114:4713-20
   PubMed Web of Science ®Google Scholar
• Witzig TE, Wiernik PH, Moore T, Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:5404-9
   PubMed Web of Science ®Google Scholar
• Smith SM, Grinblatt D, Johnson JL, Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol 2008;140:313-19.
   PubMed Web of Science ®Google Scholar
• Kiesewetter B, Troch M, Dolak W, A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT-lymphoma). Haematologica 2012;97; In press
   PubMed Web of Science ®Google Scholar
• Dutia M, DeRoock I, Chee K, Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). Blood 2009;114:abstract 1679
   Web of Science ®Google Scholar
• Samaniego F, Hagemeister F, McLaughlin P, High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011;29:abstract 8030
   Web of Science ®Google Scholar
• Fowler N, McLaughlin P, Hagemeister FB, Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol 2010;28(15s):abstract 8036
   Google Scholar
• Ahmadi T, Chong EA, Gordon A, Phase II trial of lenalidomide-rituximab +/- dexamethasone in relapsed or refractory indolent B-cell or mantle cell lymphomas resistant to rituximab. Blood 2011;118:abstract 266
   Google Scholar
• Leonard J, Jung S-H, Johnson JL, CALGB 50401: a randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. J Clin Oncol 2012;30:abstract 8000
   Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Salles GA, Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013;27:252-55
   PubMed Web of Science ®Google Scholar
• Smith SM, Cohen KS, Kline JP, Phase I trial of temsirolimus and lenalidomide in pts with re/ref lymphomas. J Clin Oncol 2012;30:abstract 8075
   Web of Science ®Google Scholar
• Cosenza M, Civallero M, Grisendi G, Combination of low doses of enzastaurin and lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Ann Hematol 2012;91:1613-22
   PubMed Web of Science ®Google Scholar
• Civallero M, Cosenza M, Bari A, Sacchi S. Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma. Expert Opin Investig Drugs 2011;20:1029-31
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun N, Ketterer N, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study. Blood 1998;92:1927-32
   PubMed Web of Science ®Google Scholar
• Hernandez-Illizaliturri FJ, Deeb G, Zinzani PL, Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011;117:5058-60
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Vose JM, Witzig TE, The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 2011;154:477-81
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 2011;29:e595-7
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pellegrini C, Gandolfi L, Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011;11:462-6
   PubMed Web of Science ®Google Scholar
• Ivanov V, Tabouret E, Chuto G, Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010;51:1758-60
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, LaPlant B, Habermann TM, Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell Lymphomas: phase I study. Leukemia 2011;25:1877-81
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Salles G, Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2012; In press
   Google Scholar
• Vitolo U, Chiapella A, Carella AM. Lenalidomide plus rituximab-CHOP21 in elderly diffuse large B-cell lymphoma (DLBCL): results of a phase I part of REAL07 trial of Italian Lymphoma Foundation (FIL). Ann Oncol 2011;22(S4):abstract 331a
   Google Scholar
• Musuraca G, Fattori PP, Ceccolini M, Prolonged 18FDG-PET negative complete remission in a heavily pretreated, elderly patient with diffuse large B cell lymphoma treated with lenalidomide, low dose dexamethasone, and colony stimulating factor (Rd-G). Am J Hematol 2011;86:79-80
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Govi S, Pileri SA, Savage KJ. Anaplastic large cell lymphoma, ALK-negative. Crit Rev Oncol Hematol 2012; In press
   Google Scholar
• Querfeld C, Kuzel TM, Guitart J, Rosen ST. Preliminary results of a phase II study of CC-5013 (lenalidomide, Revlimid®) in patients with cutaneous T-cell lymphoma. Blood 2005;106:abstract 3351
   Web of Science ®Google Scholar
• Dueck G, Chua N, Prasad A, Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. Cancer 2010;116:4541-8
   PubMed Web of Science ®Google Scholar
• Zonder JA, Barlogie B, Durie BGM, Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood 2006;108:403; Author reply Blood, 2006; 108:403
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Martinez-Banos D, Jalbrzikowski J, Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma. Leuk Lymphoma 2007;48:2330-7
   PubMed Web of Science ®Google Scholar
• Drouet L. Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers. Pathol Biol (Paris) 2008;56:195-204
   PubMedGoogle Scholar
• Klein U, Kosely F, Hillengass J, Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. Ann Hematol 2009;88:67-71
   PubMed Web of Science ®Google Scholar
• Bennett CL, Angelotta C, Yarnold PR, Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA 2006;296:2558-60
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Falanga A, American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505
   PubMed Web of Science ®Google Scholar
• Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007;131:275-7
   PubMed Web of Science ®Google Scholar
• Menon S, Habermann T, Witzig T. Lenalidomide-associated hypothyroidism. Leuk Lymphoma 2007;48:2465-7
   PubMed Web of Science ®Google Scholar
• Darabi K, Kantammei S, Wiernik PH. Lenalidomide-induced warm autoimmune hemolytic anemia. J Clin Oncol 2006;24:e59
   PubMed Web of Science ®Google Scholar
• Carver JR, Nasta S, Chong EA, Myocarditis during lenalidomide therapy. Ann Pharmacother 2010;44:1840-3
   PubMed Web of Science ®Google Scholar
• Malard F, Kroger N, Gabriel IH, Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide. Biol Blood Marrow Transplant 2012;18:314-17
   PubMed Web of Science ®Google Scholar
• Cooper DL, Pratt K, Baker J, Late afternoon dosing of plerixafor for stem cell mobilization: a practical solution. Clin Lymphoma Myeloma Leuk 2011;11:267-72
   PubMed Web of Science ®Google Scholar
• Basak GW, Jaksic O, Koristek Z, Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization. Am J Hematol 2011;86:550-3
   PubMed Web of Science ®Google Scholar
• Dasanu CA, Mitsis D, Alexandrescu DT. Hair repigmentation associated with the use of lenalidomide: graying may not be an irreversible process! J Oncol Pharm Pract. 2012; In press
   Google Scholar